Menu

Roland Nardone, Advocate for Cell-Line Authentication, Dies

The Catholic University of America professor was also known for his summer workshops on the latest techniques.

Jul 11, 2018
Kerry Grens
Roland Nardone
courtesy francis j. collins funeral home

Roland Nardone, a longtime professor at Catholic University of America who was one of the loudest voices in speaking out against cell-line contamination, died June 20. He was 90 years old.

Nardone spent more than 50 years at Catholic University, and in the later part of his career he advocated for best practices in authenticating cell lines and avoiding contamination and misidentification in tissue cultures. A founding member of the International Cell Line Authentication Committee, Nardone saw the National Institutes of Health adopt guidelines in 2016 for authentication protocols that reflected those he and his collaborators had pushed for.

“That was a gigantic service to science that probably was his biggest contribution,” says John Golin, a professor at Catholic University who had been hired by Nardone in the 1980s.

Nardone was born in New York and was a precocious student, having finished his PhD at Fordham University in 1951 at age 23. As a professor at Catholic University, Nardone studied protein synthesis, among other cell biology topics. But it was his workshops on life science techniques that remain one of his career’s most important achievements, James Greene, a professor at Catholic University, tells The Scientist.

In the 1980s, as Nardone was ending his research, he saw a need for investigators to learn new methods that were being developed, such as fluorescence-activated cell sorting (FACS). Nardone applied for a grant to get a FACS facility set up at Catholic University—one of the first outside the National Institutes of Health—and started training scientists on how to use it.

Around the same time, Nardone developed the Center for Advanced Training at Catholic University in 1983 that holds one-week-long summer workshops on various techniques. “I think maybe because of all the talents associated with his precociousness he also had prescience to be able to foresee which new technology would become more important for scientists,” says Greene.

Nardone retired in the 1990s, but did not stop working. In 2005, he took up another cause for improving research: cell-line contamination, the widespread problem of cells in culture not being the ones scientists think they are.

His 2007 letter to the US Department of Health and Human Services detailing his concerns and outlining solutions is lauded by the cell-line authentication community as having had a critical role in NIH’s later decision to push for authentication. “Through Roland’s leadership and inspiration to other leading biomedical scientists some significant breakthroughs have finally been achieved,” according to a memorial on the European Collection of Authenticated Cell Cultures’s website.

“Roland’s work shed a beacon of light on the stormy sea of cross-contaminated cell lines,” the International Cell Line Authentication Committee writes on its website. “We will miss our lighthouse and the light he shed on this important cell culture problem.”

Nardone is survived by his wife of 67 years, four children, and several grandchildren and great-grandchildren.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.